Genetic Regulation of Warfarin Metabolism and Response

Seminars in Vascular Medicine

Volumn 3, Issue 3, 2003, Pages 231-237

  Daly, Ann K ^a   Aithal, Guruprasad P ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

CYP2C9; Genetic factors; Warfarin metabolism

Indexed keywords

ACENOCOUMAROL; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; MENADIONE EPOXIDE REDUCTASE; OXIDOREDUCTASE; UNCLASSIFIED DRUG; WARFARIN;

AEROBIC METABOLISM; BLEEDING; DRUG METABOLISM; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENETIC REGULATION; GENOTYPE; HUMAN; HYDROXYLATION; REVIEW;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; WARFARIN;

EID: 0142103762     PISSN: 15289648     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-44458     Document Type: Review

References (52)

1. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999;20:342-349
2. Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000;405:857-865
3. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001;40:587-603
4. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997;73:67-74
5. Rettie AE, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome-P-450-a role for P-4502C9 in the etiology of (S)-warfarin drug-interactions. Chem Res Toxicol 1992;5:54-59
6. Hermans JJR, Thijssen HHW. Stereoselective acetonyl side-chain reduction of warfarin and analogs-partial characterization of 2 cytosolic carbonyl reductases. Drug Metab Dispos 1992;20:268-274
7. Jansing RL, Chao ES, Kaminsky LS. Phase-II metabolism of warfarin in primary culture of adult rat hepatocytes. Mol Pharmacol 1992;41:209-215
8. He MX, Korzekwa KR, Jones JP, Rettie AE, Trager WF. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. Arch Biochem Biophys 1999;372:16-28
9. http://www.imm.ki.se/CYPalleles/
10. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 2001;11:803-808
11. Aithal GP, Day CP, Kesteven PJL, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717-719
12. Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P4502C9 in a Caucasian and a black African population. Br J Clin Pharmacol 2001;52:447-450
13. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994;4:39-42
14. Rettie AE, Haining RL, Bajpai M, Levy RH. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res 1999;35:253-255
15. Crespi CL, Miller VP. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics 1997;7:203-210
16. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 1996;333:447-458
17. Shintani M, Ieiri I, Inoue K, et al. Genetic polymorphisms and functional characterization of the 5′-flanking region of the human CYP2C9 gene: in vitro and in vivo studies. Clin Pharmacol Ther 2001;70:175-182
18. Leung AYH, Chow HCH, Kwong YL, et al. Genetic polymorphism in exon 4 of cytochrome P450CYP2C9 may be associated with warfarin sensitivity in Chinese patients. Blood 2001;98:2584-2587
19. Higashi MK, Veenstra DL, Kondo LML, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002;287:1690-1698
20. Huang JD, Guo WC, Lai MD, Guo YL, Lambert GH. Detection of a novel cytochrome P-450 1A2 polymorphism (F21L) in Chinese. Drug Metab Dispos 1999;27:98-101
21. Sachse C, Brochmoller J, Bauer S, Roots I. Functional significance of a C → A polymorphism in intron I of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999;47:445-449
22. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 1999;125:803-808
23. Sata F, Sapone A, Elizondo G, et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 2000;67:48-56
24. Hsieh KP, Lin YY, Cheng CL, Lai ML, Lin MS, Siest JP, Huang JD. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos 2001;29:268-273
25. Dai D, Tang J, Rose R, Hodgson E, Bienstock RJ, Mohrenweiser HW, Goldstein JA. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 2001;299:825-831
26. Lamba JK, Lin YS, Thummel K, et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002;12:121-132
27. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998;90:1225-1229
28. Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem Biophys Res Commun 1999;259:201-205
29. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-391
30. Gillam EMJ, Guo Z, Ueng Y-F, et al. Expression of cytochrome P450 3A5 in Escherichia coli: effects of 5′ modification, purification, reconstitution conditions, and catalytic activities. Arch Biochem Biophys 1995;317:374-384
31. Margaglione M, Colaizzo D, D'Andrea G, Brancaccio V, Clampa A, Grandone E, Di Minno G. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000;84:775-778
32. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000;96:1816-1819
33. Baglin T. Avoiding overanticoagulation: pharmacogenomics or pragmatism? Thromb Haemost 2001;85:945-946
34. Margaglione M, Brancaccio V, Ciampa A, Di Minno G. Reply to Rebuttal: gene variants of the cytochrome P450CYP2C9 affect oral anticoagulation with warfarin. Thromb Haemost 2001;86:938
35. Thijssen HHW, Verkooijen IWC, Frank HLL. The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol. Pharmacogenetics 2000;10:757-760
36. Verstuyft C, Morin S, Robert A, Loriot MA, Beaune P, Jaillon P, Becquemont L. Early acenocoumarol overanticoagulation among cytochrome P4502C9 poor metabolizers. Pharmacogenetics 2001;11:735-737
37. Hermida J, Zarza J, Alberca I, Montes R, Lopez ML, Molina E, Rocha E. Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450CYP2C9 on sensitivity to acenocoumarol. Blood 2002;99:4237-4239
38. Freeman BD, Zehnbauer BA, McGrath S, Borecki I, Buchman TG. Cytochrome P450 polymorphisms are associated with reduced warfarin dose. Surgery 2000;128:281-285
39. Yasar U, Oscarson M, Eliasson E, Sjoqvist F. Mutations of the CYP2C9 gene and the response to warfarin. Surgery 2001;129:384
40. Routledge PA, Shetty HGM, White JP, Collins P. Case studies in therapeutics: warfarin resistance and inefficacy in a man with recurrent thromboembolism, and anticoagulant-associated priapism. Br J Clin Pharmacol 1998;46:343-346
41. Hallak HO, Wedlund PJ, Modi MW, Patel IH, Lewis GL, Woodruff B, Trowbridge AA. High clearance of (S)-warfarin in a warfarin-resistant subject. Br J Clin Pharmacol 1993;35:327-330
42. O'Reilly RA. The second reported kindred with hereditary resistance to oral anticoagulant drugs. N Engl J Med 1970;282:1448-1451
43. Cain D, Hutson SM, Wallin R. Warfarin resistance is associated with a protein component of the vitamin K 2,3-epoxide reductase enzyme complex in rat liver. J Biol Chem 1998;80:128-133
44. Wormhoudt LW, Commandeur JNM, Vermeulen NPE. Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Crit Rev Toxicol 1999;29:59-124
45. Wallin R, Hutson SM, Cain D, Sweatt A, Sane DC. A molecular mechanism for genetic warfarin resistance in the rat. FASEB J 2001;15:U163-U186
46. Kohn MH, Pelz HJ. A gene-anchored map position of the rat warfarin-resistance locus, Rw, and its orthologs in mice and humans. Blood 2000;96:1996-1998
47. Furuya H, Fernandez Salguero P, Gregory W, Taber H, Steward A, Gonzalez FJ, Idle JR. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 1995;5:389-392
48. Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, Rettie AE. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997;7:361-367
49. Aithal GP, Day CP, Kesteven PJL, Daly AK. Warfarin dose requirement and CYP2C9 polymorphisms-reply. Lancet 1999;353:1972-1973
50. Ogg MS, Brennan P, Meade T, Humphries SE. CYP2C9*3 allelic variant and bleeding complications. Lancet 1999;354:1124
51. Loebstein R, Yonath H, Peleg D, et al. Interindividual variability in sensitivity to warfarin-nature or nurture? Clin Pharmacol Ther 2001;70:159-164
52. Tabrizi AR, Zehnbauer BA, Borecki IB, McGrath SD, Buchman TG, Freeman BD. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg 2002;194:267-273